MRUS stock ends after Genmab completes its acquisition

Published on 09/30/2026 at 15:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The Genmab deal paid Merus holders USD 97.00 per share on December 12, 2025. MRUS stock ceased Nasdaq trading on December 30, 2025.

MRUS, NL0011375928, Illustration mit AI erstellt.

Merus N.V. (ISIN NL0011375928) became a wholly owned Genmab entity after a USD 97.00-per-share transaction, with the tender offer closing on December 12, 2025. EdgeChat reports that Nasdaq trading ended on December 30, 2025 after the back-end merger was completed.

Genmab completed the takeover

The transaction agreement was signed on September 29, 2025, and offered USD 97.00 in cash for each Merus common share. The tender process acquired 94.20 percent of the shares by December 12, 2025, according to the company history documented by EdgeChat.

The remaining minority shares were converted into the right to receive the same USD 97.00 cash consideration when the back-end merger took effect on December 29, 2025. The former Nasdaq listing therefore no longer represents an actively traded public equity, while the Merus assets continue inside Genmab's oncology portfolio.

Petosemtamab sets the next test

Genmab's September 22, 2026 conference presentation made petosemtamab the central Merus-related development milestone. According to Investing.com, Genmab added 200 patients to the frontline head and neck Phase III trial and 100 patients to the second-line study during its review of the Merus program.

The frontline trial retains objective response rate and duration of response as co-primary endpoints alongside overall survival, while the second-line study uses overall survival as its sole primary endpoint. Earlier Phase II data cited in the same transcript showed a 50.00 percent objective response rate in HPV-positive patients.

Clinical dates replace the ticker

Genmab expects the frontline petosemtamab readout in Q4 2026, with the second-line overall-survival readout guided for Q1 2027. Colorectal cancer data are scheduled for presentation at ESMO from October 23 to October 27, 2026, giving former Merus investors a dated checkpoint for the asset acquired in the transaction.

For MRUS stock, the decisive market event is historical rather than intraday: the cash consideration fixed the outcome at USD 97.00 per share, and the Nasdaq listing ended on December 30, 2025. The investment story now runs through Genmab's clinical execution and the next petosemtamab readouts.